- Conditions
- KRAS P.G12C
- Interventions
- D3S-001, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Cetuximab
- Drug
- Lead sponsor
- D3 Bio (Wuxi) Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 442 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Orange, California • Palo Alto, California • Denver, Colorado + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 626
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Melanoma, Carcinoma, Non-Small- Cell Lung
- Interventions
- SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, carboplatin
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 23
- States / cities
- Springdale, Arkansas • Los Angeles, California • San Francisco, California + 18 more
- Conditions
- Advanced Non-small Cell Lung Cancer, HER2 Mutation
- Interventions
- Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 25
- States / cities
- Newport Beach, California • San Diego, California • San Francisco, California + 20 more
- Conditions
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Durvalumab, Danvatirsen, Oleclumab, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Pittsburgh, Pennsylvania • Nashville, Tennessee
- Conditions
- Stage IIIA Non-Small Cell Lung Cancer
- Interventions
- Neoadjuvant Cisplatin, nab-paclitaxel, Adjuvant Cisplatin,nab-paclitaxel, Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 9
- States / cities
- Tampa, Florida • Atlanta, Georgia • Kansas City, Kansas + 6 more
- Conditions
- Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
- Interventions
- TAS6417
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 9
- States / cities
- Henderson, Nevada • Las Vegas, Nevada • Canton, Ohio + 1 more
- Conditions
- Lung Cancer
- Interventions
- Alimta
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neoplasms
- Interventions
- MK-0482, pembrolizumab, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin, Pemetrexed
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Hackensack, New Jersey • San Antonio, Texas
- Conditions
- Solid Tumors
- Interventions
- BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC, Temozolomide, Pumitamig, Pemetrexed, Carboplatin, Nab-paclitaxel, Gemcitabine, Paclitaxel
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 16
- States / cities
- San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 10 more
- Conditions
- Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
- Interventions
- AZD1775, AZD1775 Matching Placebo, pemetrexed, carboplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 8
- States / cities
- Englewood, Colorado • Fort Myers, Florida • Orlando, Florida + 5 more
- Conditions
- Resectable Non-small Cell Lung Cancer
- Interventions
- Fianlimab, Cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 8
- States / cities
- Clermont, Florida • Chicago, Illinois • Westwood, Kansas + 5 more
- Conditions
- Lung Cancer
- Interventions
- Pembrolizumab, Epacadostat, Platinum-based chemotherapy, Placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 21
- States / cities
- Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 18 more
- Conditions
- Cancer of Head and Neck
- Interventions
- Omeprazole, Carboplatin, 5FU, Paclitaxel, Pemetrexed
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Stage I Lung Non-Small Cell Cancer AJCC v7, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Carboplatin, Cisplatin, Docetaxel, Ipilimumab, Nivolumab, Pemetrexed
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Head and Neck Cancer
- Interventions
- Pemetrexed plus Gemcitabine
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-Small Cell Carcinoma of Lung, TNM Stage 4
- Interventions
- Arm A, Arm B
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Pemetrexed, Gemcitabine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Columbia, Missouri • Kansas City, Missouri + 2 more
- Conditions
- Lung Cancer
- Interventions
- erlotinib hydrochloride, pemetrexed disodium, docetaxel
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 13
- States / cities
- Detroit, Michigan • New York, New York • Cleveland, Ohio + 3 more
- Conditions
- Non Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Urothelial Carcinoma, Malignant Mesothelioma
- Interventions
- Cabozantinib, Pemetrexed
- Drug
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer
- Interventions
- Cemiplimab, Investigator Choice (IC) Chemotherapy
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Orange, California + 8 more
- Conditions
- Non-Small Cell Lung Cancer Metastatic
- Interventions
- Durvalumab, Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Cancer
- Interventions
- IC83/LY2603618, pemetrexed
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Ovarian Cancer, Peritoneal Cancer
- Interventions
- pemetrexed
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- Female only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab, Carboplatin, Pemetrexed, Alectinib, Selpercatinib, Selumetinib, Etoposide, Cisplatin, Datopotamab deruxtecan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 16
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 11 more